OpenEvidence is an AI healthcare startup based in Cambridge, Massachusetts, offering a chatbot designed to assist physicians in making better decisions at the point of care.
OpenEvidence and Doximity have settled a legal dispute involving allegations of corporate espionage, doctor impersonation, defamation, and platform misuse. A federal judge dismissed the case with prejudice.
Researchers analyzed how 950,000 US clinicians used OpenEvidence from January 2024 to June 2026. Most queries concerned clinical decisions, particularly treatment and patient management.
OpenEvidence and Johns Hopkins Medicine will develop an AI focused medical education model and clinical tools that combine research evidence with patient histories.
An independent study by Stanford and Harvard researchers found that physicians chose OpenEvidence more frequently than ChatGPT, Claude, Gemini, and all other external AI chatbots combined when given unrestricted access to clinical tools.
OpenEvidence has acquired Amaro, an AI-native advertising company backed by Google Ventures, to enhance its healthcare platform capabilities.
OpenEvidence has developed an AI system that scored a perfect 100% on the United States Medical Licensing Examination (USMLE), as announced in a press release.
Daily report covering major AI developments and industry news, with both top stories and complete market updates
